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Goals: The aim of this study was to assess the histopathologic
characteristics of colorectal carcinomas (CRC) in patients with
Crohn’s disease (CD).
Background: A higher frequency of microsatellite instability (MSI)
is seen in mucinous compared with nonmucinous CRC which
suggests that its pathogenesis involves distinct molecular pathways.
Several publications reported a higher percentage of mucinous
adenocarcinoma in CD patients with CRC. So far, there has been
no investigation of MSI in CD patients with mucinous CRC.
Study: The medical records of patients who underwent surgery for CRC
were reviewed and those with a history of CD identiﬁed. The data of
histologic classiﬁcation and MSI status of the tumor were investigated.
Results: Fourteen patients with CD-associated CRC were identiﬁed
(5 female, 9 male) resulting in 20 CRC in total. Histologic inves-
tigation revealed 7 adenocarcinomas without a mucinous or signet
ring cell component. All other CRCs harbored a mucinous (n=11)
and/or signet ring cell (n=6) component. All tumors assessed for
MSI were found to be microsatellite stable.
Conclusions: Our data indicate that CRCs with signet ring cell and
mucinous components were much more common in patients with
CD than in patients with sporadic CRC. This observation suggests
that CRC in CD represent an own entity with distinct histo-
pathologic and molecular features. This may implicate potential
consequences for diagnosis and therapy of CRC in CD in the
future as well as new factors to identify patients with an increased
risk for developing CRC in CD.
Key Words: Crohn’s disease, mucinous adenocarcinoma, micro-
satellite instability
(J Clin Gastroenterol 2017;00:000–000)
The association of colorectal carcinomas (CRC) withinﬂammatory bowel disease is well established for
ulcerative colitis (UC),1 though recent data suggest that it
might have been overestimated in the past or it might be
decreasing.2 The carcinogenic risk for Crohn’s disease (CD)
is less investigated and thus, its magnitude remains con-
troversial. The descriptions range from no increased CRC
compared with the normal population risk up to being
comparable with the CRC risk in UC.1,3–6 In terms of
prognosis a recent meta-analysis showed a trend toward an
adverse prognosis in patients with CRC and CD compared
with sporadic CRC patients.7 The last ECCO workshop of
the European Crohn’s and Colitis Organization on CRC in
inﬂammatory bowel disease conﬁrmed a worse outcome in
this population.2
HISTOLOGIC SUBTYPES OF COLORECTAL
ADENOCARCINOMA
Mucinous adenocarcinoma (MAC) is a histologic
subtype of CRC where secreting acini produce large pools
of extracellular mucus as the predominant component of
the carcinoma. Mucinous accounts for 5% to 15% of all
CRC, while some authors describe in smaller series even
lower and higher rates.8–10 The World Health Organization
(WHO) deﬁnes adenocarcinoma as mucinous when >50%
of the lesion is extracellular mucus. If <50% but >10%
of the lesion is composed of mucus it is designated as
adenocarcinoma with mucinous component. Several pub-
lications have reported a higher percentage of MAC in CD
patients with CRC; however, the magnitude of this varies
considerably.11–13
Signet ring cell carcinoma (SRCC) is a less frequent
entity. The WHO describes SRCC as a carcinoma com-
posed of >50% signet ring cells, which are deﬁned by an
accumulation of intracellular mucin. A CRC where <50%
but >10% of the lesion is composed of signet ring cells is
deﬁned as CRC with signet ring component. In the
National Cancer Data Base (NCDB) of the American
College of Surgeons and the American Cancer Society, 1%
of the patients with sporadic CRC show a SRCC.10
Although older data indicate a much higher proportion of
SRCC in CD,12 a more recent study failed to conﬁrm these
results.11
Both forms (MAC and SRCC) have been reported to
involve poorer prognosis to a diﬀerent extent. Although
MAC of the colon did not show any diﬀerent prognosis to
non-MACs in the NCDB analysis, MACs of the rectum
showed a signiﬁcantly worse prognosis compared with
nonmucinous rectal cancer.10 This may be related to the
fact that MACs showed a poorer response to neoadjuvant
chemoradiation than nonmucinous CRC, a treatment reg-
ularly applied in rectal cancer.14,15 In a meta-analysis, a
mucinous component in adenocarcinoma was also neg-
atively correlated with survival.16 SRCCs are associated
with a higher risk of death compared with nonmucinous,
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non–signet ring cell adenocarcinomas in both colon and
rectum.10
In this study, we present the clinical and histopatho-
logic data of CRC patients with CD in a single-center
database.
METHODS
The study protocol was reviewed and approved by the
local institutional ethics committee (2013-570N-MA, 2013-
821R-MA). The study was performed according to the
Declaration of Helsinki.
Patients
A retrospective analysis of the surgical database for
CRC at our institution was performed. The medical records
of 2067 patients who underwent surgery for CRC between
01/1999 and 12/2015 were reviewed and those with a history
of CD were identiﬁed. The data were evaluated with regard
to characteristics of CD as well as CRC.
Pathology Investigation
Two pathologists (T.G., D.H.) examined hematoxylin
and eosin-stained sections of each case. Histologic grading
according to WHO classiﬁcation for CRC (not otherwise
speciﬁed) was performed.17
Microsatellite Instability (MSI)
MSI phenotype was detected indirectly by loss of DNA
mismatch repair protein expression (immunohistochemistry)
and directly by microsatellite analysis [pathological complete
remission (PCR)].
MSI Detection (Immunohistochemistry)
Tissue sections of 2 to 3mm were mounted on self-
coated slides followed by the semiautomatic process of
deparaﬃnization and epitope retrieval as published pre-
viously.18 Primary antibodies were then applied targeting
the epitopes MSH2, MSH6, MLH1, and PMS2 (all DAKO,
MLH1: 1:50; MSH2: 1:100; MSH6: 1:10; PMS2: 1:100).
Antibody binding was visualized using the Envision System
as described by the manufacturer (DakoCytomation,
Glostrup, Denmark). Only slides with distinct positive
nuclear staining in the basal crypt cells of normal mucosa
and stromal and inﬂammatory cells were evaluated. Tumor
samples lacking nuclear staining MSH2, MSH6, MLH1,
and/or PMS2 were considered MSI.
MSI Detection (PCR)
Histology-based macrodissected tumor areas and nor-
mal tissue were selected and digested using proteinase K.
DNA was extracted according to conventional protocols.19
For microsatellite analyses, we used a panel of 8 well-
established pairs of microsatellite primers that consisted of 5
mononucleotid (BAT26, BAT25, NR21, NR24, MONO27)
and 3 dinucleotid (D2S123, D5S346, D17S250) repeat
markers. The primer sequences for the ampliﬁcation of
microsatellite repeats were retrieved from the Genome Data
Base. MSI was detected as the appearance of PCR bands of
diﬀerent lengths in tumor tissue not seen in the genomic
DNA from normal tissue. Tumor was considered micro-
satellite stable (MSS) if none of the 8 PCRs showed band
shift. MSI-low was deﬁned as instability in only 1 marker;
high MSI (MSI-H) as instability in >1 marker and if no
marker showed instability the tumor was considered MSS.
RESULTS
Patients
Fourteen patients with CD undergoing surgery for
CRC were identiﬁed. The patients’ characteristics are dis-
played in Table 1. One patient had concomitant primary
sclerosing cholangitis. None of the patients had a family
history suspicious to hereditary colorectal cancer. The use
of Crohn’s medication was diﬃcult to trace completely in
the retrospective data collection. Most of the patients had a
treatment with 5-aminosalicylic acid, medication with other
drugs cannot be reported conclusive. At the time of diag-
nosis, the patients in median had a 26-year history of CD.
One patient with simultaneous diagnosis of CD and CRC
showed symptoms for >10 years, during which time he was
treated for irritable bowel syndrome. Diagnosis was
delayed because the patient never agreed to a colonoscopy
until symptoms were beyond all bearing. Because of the
discrepancy between symptoms and diagnosis, this patient
was excluded from the calculation of median duration of
CD before diagnosis of CRC. Twelve patients underwent
tumor resection according to oncologic principles and all
but 1 tumor were resected in sano (R0). Two patients
underwent only exploration and adhesiolysis when peri-
toneal carcinomatosis became evident.
From a total of 20 CRCs in 14 patients, histologic
grading could be undertaken in 16. In 4 CRC, grading
could not be estimated: 2 of these patients had undergone
neoadjuvant treatment; tumor regression grade was 3
according to the Dworak classiﬁcation system in both cases.
The 2 other patients showed peritoneal carcinomatosis and
only biopsies were taken (one of them also had preoperative
chemoradiation); no T stage and no N stage could be
deﬁned in these 2 patients, too. In 1 patient, no lymph
nodes could be retrieved; this patient previously underwent
sphincter-preserving proctocolectomy due to Crohn’s col-
itis; 18 years later, the subsequent rectal cancer in the rectal
stump was diagnosed.
Three patients had synchronous CRC. One patient
had 4 carcinomas in 3 localizations, 1 patient 3 synchro-
nous carcinomas in 2 diﬀerent colon segments, 1 patient 2
carcinomas in diﬀerent localizations.
One tumor (6.25%) showed good diﬀerentiation (G1),
6 (37.5%) were moderately diﬀerentiated (G2), and 9
(56.25%) were poorly diﬀerentiated (G3).
Localization of CRC can be seen in Table 2. Three
patients had synchronous CRCs in diﬀerent localizations.
In 1 patient, concomitant adenocarcinomas of the ascend-
ing colon and hepatic ﬂexure were present. In another
TABLE 1. Patients’ Characteristics
Characteristics n=14
Age (y) (median; range) 50.5 (28-76)
Sex (male/female) 9/5
Age at diagnosis of Crohn’s disease (y)
(median; range)
22.5 (12-58)
Duration of Crohn’s disease (y) (median; range) 26 (4-41)
Crohn’s colitis [n (%)] 8 (57.1)
Patients with synchronous colorectal carcinomas at
diﬀerent localizations [n (%)]
3 (21.4)
Patients with history of colorectal cancer
(Metachronous colorectal cancer) [n (%)]
1 (7.1)
History of ileocecal resection [n (%)] 4 (28.6)
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patient, 4 diﬀerent carcinomas were found in 3 local-
izations: 1 in the ascending colon, 2 in the transverse colon,
and 1 in the rectum. At least, 1 patient simultaneously had 3
carcinomas: 1 in the ascending colon and 2 in the sigmoid
colon. In addition, this patient had diagnosis of CD and
CRC at the same time. Before surgery, preoperative diag-
nosis of a high-grade intraepithelial neoplasia in a stenosis
of the sigmoid colon was established and suspicion of CD
arose from an additional detectable conglomerate tumor
between sigmoid colon and terminal ileum. Radical resec-
tion was performed for the sigmoid colon and due to the
conglomerate tumor an ileocecal resection was performed,
too. However, the latter resection was not performed
according to oncologic standards. On subsequently histo-
logic work-up, all of the carcinomas were resected in sano
(R0). The patient subsequently received an oncological
salvage resection of the right hemicolon without any further
signs of a tumor or inﬁltrated lymph nodes. Histopatho-
logic stages of all patients can be seen in Tables 2 and 3.
Ongoing active inﬂammation was seen in 8 patients; in
another 3 patients only moderate or discontinuous inﬂam-
mation was diagnosed. In 2 cases, information on inﬂam-
matory activity was not retrievable from the pathology or
colonoscopy reports. The absence of any signs of ongoing
inﬂammation was reported in 1 patient.
Neoadjuvant chemoradiation was applied in 3
patients; 1 of them was subsequently diagnosed with peri-
toneal carcinomatosis during surgery; no resection was
performed. Radical resection could be performed in the
other 2 patients.
Indication for adjuvant chemotherapy was conﬁrmed
in 7 cases; however, only 4 patients received postoperative
chemotherapy due to anastomotic leakage in 1 case and
wound breakdown in the other 2.
Palliative chemotherapy was planned in 2 cases with
peritoneal carcinomatosis; one of the patients deceased
before treatment initiation.
Four patients deceased during follow-up due to
progress of the malignant disease (Table 4).
Histopathologic Evaluation and MSI Status
Histologic investigation conﬁrmed 7 of 18 cases
(38.9%) as an adenocarcinoma without mucinous or signet
ring cell component (Table 5). The paraﬃn blocks of 2
tumors were not available for investigation.
All other tumors were classiﬁed as CRCs with muci-
nous and/or signet ring cell component. We refrained from
using the terms “mucinous adenocarcinoma” and “signet
ring cell carcinoma” in the histologic classiﬁcation of the
CD-associated CRCs because for 2 patients only biopsy
material was available, which did not allow an accurate
quantiﬁcation (>/<50%) of the extracellular mucin pools
as is required by the WHO classiﬁcation. In the analysis of
MSI status, no tumor showed MSI.
DISCUSSION
We present a single-center study of a tertiary referral
center on clinical and histopathologic characteristics of
CRC in CD. The risk for development of CRC in CD is still
controversial and there is no scientiﬁc evidence to deﬁne
surveillance intervals in CD. Current treatment guidelines
in Germany recommend regular surveillance colonoscopies
at least every 2 years beginning from the eighth year
of CD—but solely for patients with extensive Crohn’s
colitis.20 The deﬁnition of extensive colitis is according to
the Montreal classiﬁcation for UC what means that the
TABLE 2. Distribution of Tumor Localizations and
Histopathologic Stages
Distribution of Tumor Localizations (n=20) n (%)
Right hemicolon 6 (30)
Transverse colon 2 (10)
Left hemicolon 0 (0)
Sigmoid 3 (15)
Rectum 6 (30)
Fistula-in-ano cancer 3 (15)
Histopathologic tumor stage
T1 1 (5)
T2 6 (30)
T3 5 (25)
T4 6 (30)
Tx 2 (10)
Histopathologic lymph node stage
N0 14 (70)
N1 1 (5)
N2 2 (10)
Nx 3 (15)
TABLE 3. Systemic Tumor Burden of the Patients (n = 14)
Distant Metastasis at Primary Surgery With Regard
to Patients (n=14) n (%)
M0 10 (71.4)
M1 4 (28.6)
Mx 0
UICC classiﬁcation (n=14)
UICC I 2 (14.3)
UICC II 5 (35.7)
UICC III 3 (21.4)
UICC IV 4 (28.6)
UICC indicates Union internationale contre le cancer.
TABLE 4. Follow-up Results
Follow-up Results (n=14)
Median (Range)
Mean (STD)
Follow-up (mo) 14.5 (1-60)
24.8 (±22)
Progression-free survival (mo) 14.5 (0-60)
22.4 (±22.5)
Overall survival (mo) 14.5 (1-60)
24.8 (±22)
n (%)
Local recurrence 0
Distant metastasis 4 (28.6)
Cancer-related death 4 (28.6)
TABLE 5. Histopathologic Characteristics
Tumor Characteristics n (%)
CRC with mucinous component 11 (61.1)
CRC with signet ring cell component 6 (33.3)*
CRC without mucinous or signet ring cell component 7 (38.9)*
*Combination of mucinous and signet ring cell components in 6
patients.
CRC indicates colorectal carcinomas.
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involvement of the colitis extends proximal to the splenic
ﬂexure.21 For CD patients without colitis, surveillance
recommendations are not given. Five of the patients in our
cohort had the screening colonoscopies as for the normal
population at the age over 50.
The frequency of CRCs decreases in patients without
reference to CD from the rectum to proximal localizations.
In CD patients, a speciﬁc anatomic distribution of CRC has
not yet been described. Some authors describe a predom-
inance of rectal cancer22; others have reported a 2-peak
distribution in the right hemicolon as well as in the rectum,
but much less in the left hemicolon.11 This distribution was
also seen in our cohort. However, it was not possible to
establish a correlation between the localization of the car-
cinoma and disease-free survival as some of the patients
had synchronous carcinomas in diﬀerent segments and
furthermore the numbers are too low to allow any mean-
ingful conclusions.
We found interesting histopathologic and molecular
features that set CRC in CD apart from sporadic CRC.
First, adenocarcinomas with a mucinous component
are overrepresented in our cohort of colorectal cancers. In
nonselected CRC collectives the frequency of CRCs with
mucinous phenotype varies between 5% and 15%10; in our
series we found 61% MACs.
In 2007 Svrcek et al11 reported one of the rare studies
on the incidence of MAC in CD patients. Their ﬁndings
concerning patient’s age, duration of CD as well as dis-
tribution of the carcinoma in the colorectum were quite
similar to our results. Earlier studies reporting CRC in CD
patients also displayed a higher proportion of MAC.12,23 In
2010, Ouaı¨ssi et al24 reported 14 cases of colorectal adeno-
carcinoma in CD patients; 35% of them showed mucinous
diﬀerentiation. In a recently published study of 5 colorectal
adenocarcinomas in CD patients all showed mucinous his-
topathology.13 However, in this study all patients had in the
past already undergone total colectomy and then had a ﬁs-
tula-in-ano cancer. The signiﬁcantly higher number of MAC
on the basis of chronic perianal ﬁstula is known.22,25,26 In
our cohort, 2 of the 3 patients with ﬁstula-in-ano cancer
showed a mucinous diﬀerentiation.
The higher incidence of MAC in CD patients could be
correlated to the higher incidence of right-sided colon
cancer. In a meta-analysis including 20 studies MAC in
general is more often localized proximal to the splenic
ﬂexure and less common in male patients.16 A recently
published large single-center study conﬁrmed the ﬁndings
of more right-sided colon cancer with mucinous histo-
pathology.27 We evaluated 11 adenocarcinomas with a
mucinous component in our cohort. Only 2 were situated
proximal to the splenic ﬂexure.
Second and most striking is the negative correlation of
MAC and MSI in CD patients.
MSI, which is found in 15% to 20% of sporadic CRC,
reﬂects the inactivation of DNA mismatch repair.28,29 In
nonpreselected CRC series, MAC include between 30% and
60%MSI cases30–32; in the few existing studies, SRCC shows
MSI rates of 31% to 38%.32,33 In general, distinctive features
including a better prognosis have been demonstrated for
CRC whenMSI is present.34 However, this contrasts with the
more advanced status of MAC at diagnosis and the worse
survival of patients with mucinous rectal cancer and signet
ring cancer in both colon and rectum in large studies.10,32 In
view of the heterogenous data in the literature, a deﬁnite
conclusion concerning the clinical inﬂuence of MSI in MAC
cannot be drawn.16,35 A recently published study failed to
show that MSI status is relevant for prognosis in colorectal
SRCC—probably due to limited statistical power.35
Generally, a higher frequency of MSI has been
reported for mucinous (27% to 36%) compared with non-
MAC of the colorectum (about 15%).31,32,34,36,37 This
correlation of MAC and MSI is already established in such
a way that analysis of MSI status has been integrated in
guidelines.38
In non-MAC, MSI-H is linked to a better prognosis
than microsatellite stability.34 The association of MSI-H
with less aggressive tumor growth, lower tumor stage, and
better outcome is also assumed for MAC.30,35,37,39 How-
ever, the heterogenous data prevent conclusive statements.
Four publications could be retrieved for a meta-analysis
containing data on survival in MAC, stratiﬁed by MSI
Status.16,30,31,39,40 Three of them could show a better sur-
vival for MSI high in MAC compared with MSS-
MAC.16,30,31,40 However, 1 study showed a worse survival
in MSI-MAC.39
Against this background, it is of particular interest that
none of the MACs identiﬁed in CD in the presented study
displayed MSI. The study byMalvi et al13 on 5 ﬁstula-in-ano
cancers had the same ﬁndings. However, the description of a
clearly increased rate of MAC and SRCC in CD patients
with colon or rectal cancer and the correlation to a so far not
explainable high rate of MSS in both colon and rectal cancer
has not been made yet.
Although the higher percentage of MSI-H in MAC
independent from CD suggests that its pathogenesis might
involve distinct molecular pathways,34 the ﬁnding in CD
patients raises the question of another speciﬁc pathogenesis.
The higher percentage of MSS status in MAC of CD
patients has not yet been investigated. Svrcek et al11
described a higher frequency of MAC in colorectal cancer
of CD patients but completely missed to investigate the
MSI status.
The third issue concerns the high percentage of carci-
nomas with a signet ring cell component in our cohort.
SRCC was ﬁrst described by Parham41 in 1923 as a subtype
of CRC that accounts for only 1% of CRC. SRCC is
associated with an advanced tumor stage at diagnosis and a
lower survival rate compared with mucinous and non-
mucinous CRC in both colon and rectum.9,10 On an aver-
age, patients with signet ring cell adenocarcinoma of the
colorectum are younger than other CRC patients.10 As in
mucinous adenocacinoma, SRCC tend to be in the right
hemicolon more often.10 Our cohort included 6 patients
with CRC with a signet ring cell component. One of them
was in the cecum, the others were located in the sigmoid
(n=1) or in the rectum (n=4).
An interesting publication by Bo¨rger et al42 showed
that signet ring cells within mucinous carcinomas correlate
with increased T stage and poorer prognosis. A just recently
published study showed that even a minor signet ring cell
component is correlated to higher mortality in colon ade-
nocarcinoma but not in rectal cancer.35 MSI-H rates are
described to be higher in SRCC of the colorectum.32
A comparison with former results of SRCC in CD is
not possible as this is, to the best of our knowledge, the ﬁrst
such report. According to this, no comparison with MSI
rates in CD patients with SRCCs of the colorectum can
be drawn but it brings again to mind that pathogenesis
of CRC in CD patients might be dissimilar from other
sporadic CRC.
Galata et al J Clin Gastroenterol  Volume 00, Number 00, ’’ 2017
4 | www.jcge.com Copyright r 2017 Wolters Kluwer Health, Inc. All rights reserved.
Copyright r 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
This paper can be cited using the date of access and the unique DOI number which can be found in the footnotes.
In a meta-analysis mucinous colorectal adenocarci-
noma showed a slightly worse survival rate than non-MAC
with a hazard ratio of 1.0616
In fact, mucinous CRCs are often diagnosed at a more
advanced stage and most of the earlier studies suggesting an
adverse prognosis for MAC did not analyze stage-by-
stage.10 A large study of the NCDB including 250,000
patients indicated that MACs have a worse prognosis in the
rectum but not in the colon.10 This could reﬂect its poorer
response to neoadjuvant treatment, which is applied in the
rectum but not in the colon.14
Comparison in non–CD-related sporadic MACs and
SRCCs show that MACs are less responsive to chemo-
therapy43,44 as well as to chemoradiation than non-
mucinous non–signet ring cell CRC.15 As far as we know
SRCC seems to have a comparable beneﬁt from chemo-
therapy as common colorectal adenocarcinomas.45 We
cannot comment on response to neoadjuvant or adjuvant
treatment from our data as only 3 patients underwent
neoadjuvant chemoradiation. One of them showed devas-
tating progress under treatment.
The course of CRC patients with CD seems to be sig-
niﬁcantly worse than that of other CRC sporadic patients.
In our cohort, median age was 50.5 years at the time of
CRC diagnosis; compared with epidemiologic data for
Germany, this is >20 years below the average age of all
patients diagnosed with sporadic CRC.46 Moreover, after a
follow-up of 18 months more than one quarter of the
patients (n=4; 28.6%) had distant metastasis and died
from cancer.
A publication by Ekbom et al47 from 1990 including 12
cases of CRC in CD showed a higher risk for developing
CRC in patients with an early onset of CD. However, a later
publication by Brackmann et al48 including 6 cases of CRC in
CD was unable to reproduce these ﬁndings. In contrast again,
a nationwide survey from the Netherlands identiﬁed late
diagnosis of inﬂammatory bowel disease to be associated with
early development of CRC.49 In that study, median time from
diagnosis of CD to CRC was 13.6 years. In total, 30% of the
patients developed CRC within 8 years after diagnosis of CD
and this subgroup was of signiﬁcantly more advanced age at
the time of diagnosis of CD. In our cohort the patients had
median disease duration of 26 years until development of
CRC. Two patients developed CRC within 10 years after
diagnosis of CD, which is a bit faster than reported in some
studies,48,50 but much less than in the nationwide survey from
the Netherlands.49 These 2 patients were the oldest in our
cohort at the time of diagnosis of CD with the age of 44 and
59, respectively.
The risk for developing CRC in patients with CD is
increased, as is the risk for an unfavorable outcome. Yet up
to now no speciﬁc risk factors could be identiﬁed in CD
patients. Our data suggest that CRC with a mucinous and/
or signet ring cell component is far more common in
patients with CD than in other sporadic CRC. In con-
junction with the results of MSI analysis, this is of partic-
ular interest as the lack of MSI in patients with CRC in CD
indicates that MAC in CD represents an own biological
entity that warrants further investigation.
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